Concurrent Experience of Self-Reported Mental Health Symptoms and Problematic Substance Use During the First Two Years of the COVID-19 Pandemic Among Canadian Adults: Evidence from a Repeated Nationwide Cross-Sectional Survey.

This study was aimed at identifying the prevalence of concurrent experience, poor mental health and problematic substance use, and its associated factors, among Canadian adults during the COVID-19 pandemic. A nationwide repeated cross-sectional sample of 14,897 Canadian adults (quota-sampled, weighted) were recruited on ten occasions between October 2020 and March 2022 using online panels. Concurrent experience was defined as mild to severe symptoms of depression (Patient Health Questionnaire-9) and/or anxiety (Generalized Anxiety Disorder-7) AND meeting screening criteria for problematic cannabis (Cannabis Use Disorder Identification Test-Revised) and/or problematic alcohol use (Alcohol Use Disorder Identification Test).

[Genetics in nephrology - any news?].

While genetic kidney diseases were long regarded as a rare cause of kidney failure, it has been shown in recent years that they account for a relevant proportion of cases. In cohorts of kidney transplant recipients, a monogenic cause is found in up to 30% of cases. Identifying the genetic cause of kidney disease has become much easier thanks to technological advances in DNA sequencing.

Effectiveness and safety of immunoadsorption as a rescue treatment of inflammatory myopathies: report of three cases and literature review.

Idiopathic inflammatory myopathy (IIM) summarizes rare, systemic autoimmune conditions primarily characterized by inflammatory damage to the skeletal muscle. Although primary damage occurs to the muscle, these IIM-related conditions involve other organs, including the skin, lungs, upper gastrointestinal tract, joints, and heart. While many patients have an adequate response to immunosuppressive treatment, some patients develop rapidly progressive and treatment-resistant life-threatening courses.

Estimating additional health and social costs in eating disorder care for young people during the COVID-19 pandemic: implications for surveillance and system transformation.

Background: The impact of the COVID-19 pandemic on young people with eating disorders (EDs) and their families was profound, with surging rates of hospitalizations and referrals reported internationally. This paper provides an account of the additional health and social costs of ED care for young people living in Canada incurred during the COVID-19 pandemic, drawing attention to the available data to inform these estimates while noting gaps in data capacities to account for a full view of the ED system of care.

Methods: Three methodologies were used to capture costs: (1) provincial administrative data holdings available at the Canadian Institute of Health Information (CIHI) were used by Deloitte Access Economics to conduct analyses on costs related to hospitalizations, emergency room visits, outpatient visits with physicians and loss of well-being from being on a waitlist.